

Zuyu Liang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3368609/publications.pdf>

Version: 2024-02-01

309
papers

8,261
citations

94269

37
h-index

71532

76
g-index

334
all docs

334
docs citations

334
times ranked

13021
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping the Mouse Cell Atlas by Microwell-Seq. <i>Cell</i> , 2018, 172, 1091-1107.e17.	13.5	1,068
2	Construction of a human cell landscape at single-cell level. <i>Nature</i> , 2020, 581, 303-309.	13.7	695
3	Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. <i>Nature Biotechnology</i> , 2015, 33, 175-178.	9.4	395
4	The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology. <i>Journal of Hematology and Oncology</i> , 2018, 11, 33.	6.9	233
5	A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value. <i>Blood</i> , 2014, 124, 1645-1654.	0.6	232
6	Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte. <i>Stem Cell Research and Therapy</i> , 2019, 10, 95.	2.4	211
7	T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT. <i>Blood</i> , 2014, 124, 2735-2743.	0.6	171
8	Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. <i>Journal of Hematology and Oncology</i> , 2016, 9, 70.	6.9	151
9	The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. <i>Journal of Hematology and Oncology</i> , 2021, 14, 145.	6.9	124
10	Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/ β -catenin signaling pathway. <i>Journal of Hematology and Oncology</i> , 2015, 8, 1.	6.9	122
11	CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 2764-2772.	3.2	122
12	The consensus on the monitoring, treatment, and prevention of leukemia relapse after allogeneic hematopoietic stem cell transplantation in China. <i>Cancer Letters</i> , 2018, 438, 63-75.	3.2	116
13	Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 3297-3306.	3.2	106
14	Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. <i>Blood</i> , 2015, 125, 2771-2778.	0.6	102
15	Mapping human pluripotent stem cell differentiation pathways using high throughput single-cell RNA-sequencing. <i>Genome Biology</i> , 2018, 19, 47.	3.8	96
16	Myeloid-Specific Disruption of Tyrosine Phosphatase Shp2 Promotes Alternative Activation of Macrophages and Predisposes Mice to Pulmonary Fibrosis. <i>Journal of Immunology</i> , 2014, 193, 2801-2811.	0.4	93
17	Acupuncture combined with methylcobalamin for the treatment of chemotherapy-induced peripheral neuropathy in patients with multiple myeloma. <i>BMC Cancer</i> , 2017, 17, 40.	1.1	79
18	Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 150.	6.9	79

#	ARTICLE	IF	CITATIONS
19	Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1092-1098.	2.0	79
20	The many substrates and functions of NEDD4-1. <i>Cell Death and Disease</i> , 2019, 10, 904.	2.7	70
21	Antithymocyte Globulin for Matched Sibling Donor Transplantation in Patients With Hematologic Malignancies: A Multicenter, Open-Label, Randomized Controlled Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3367-3376.	0.8	69
22	Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia. <i>Experimental Hematology and Oncology</i> , 2017, 6, 10.	2.0	64
23	Engineering better chimeric antigen receptor T cells. <i>Experimental Hematology and Oncology</i> , 2020, 9, 34.	2.0	64
24	Raf kinase inhibitor protein mediates intestinal epithelial cell apoptosis and promotes IBDs in humans and mice. <i>Gut</i> , 2017, 66, 597-610.	6.1	61
25	Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. <i>Journal of Hematology and Oncology</i> , 2017, 10, 113.	6.9	60
26	Mechanisms and rejuvenation strategies for aged hematopoietic stem cells. <i>Journal of Hematology and Oncology</i> , 2020, 13, 31.	6.9	59
27	Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 42.	6.9	56
28	Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. <i>Cancer Letters</i> , 2015, 356, 443-453.	3.2	52
29	Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. <i>BMC Cancer</i> , 2021, 21, 606.	1.1	52
30	Interleukin-6 signaling regulates hematopoietic stem cell emergence. <i>Experimental and Molecular Medicine</i> , 2019, 51, 1-12.	3.2	51
31	Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1898-1907.	2.0	48
32	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	3.3	47
33	The distributions of HLA-A, HLA-B, HLA-C, HLA-DRB1 and HLA-DQB1 allele and haplotype at high-resolution level in Zhejiang Han population of China. <i>International Journal of Immunogenetics</i> , 2019, 46, 7-16.	0.8	46
34	scMAGeCK links genotypes with multiple phenotypes in single-cell CRISPR screens. <i>Genome Biology</i> , 2020, 21, 19.	3.8	46
35	A single-cell survey of cellular hierarchy in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2020, 13, 128.	6.9	45
36	Hematopoietic stem cell transplantation activity in China 2019: a report from the Chinese Blood and Marrow Transplantation Registry Group. <i>Bone Marrow Transplantation</i> , 2021, 56, 2940-2947.	1.3	43

#	ARTICLE	IF	CITATIONS
37	First-in-Man CD123-Specific Chimeric Antigen Receptor-Modified T Cells for the Treatment of Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3778-3778.	0.6	43
38	Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1347-1356.	1.5	40
39	Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis. <i>Hematology</i> , 2019, 24, 199-207.	0.7	40
40	Association between DNMT3A Mutations and Prognosis of Adults with De Novo Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e93353.	1.1	39
41	<sc>NDR</sc>1 protein kinase promotes <sc>IL</sc>17 and <sc>TNF</sc>-mediated inflammation by competitively binding <sc>TRAF</sc>3. <i>EMBO Reports</i> , 2017, 18, 586-602.	2.0	39
42	Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 2022.	2.2	39
43	Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia. <i>Molecular Therapy</i> , 2021, 29, 645-657.	3.7	39
44	Risk and prognostic factors of transplantation-associated thrombotic microangiopathy in allogeneic haematopoietic stem cell transplantation: a nested case control study. <i>Hematological Oncology</i> , 2017, 35, 821-827.	0.8	37
45	The Plasticity of Mesenchymal Stem Cells in Regulating Surface HLA-I. <i>IScience</i> , 2019, 15, 66-78.	1.9	37
46	A retrospective comparison of allogeneic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 1208-1217.	1.3	37
47	CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. <i>Cancer Immunology Research</i> , 2021, 9, 1061-1070.	1.6	37
48	<sc>RKIP</sc> and <sc>TBK</sc>1 form a positive feedback loop to promote type I interferon production in innate immunity. <i>EMBO Journal</i> , 2016, 35, 2553-2565.	3.5	36
49	Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. <i>Blood</i> , 2022, 139, 3376-3386.	0.6	36
50	Invasive fungal infection in allogeneic hematopoietic stem cell transplant recipients: single center experiences of 12 years. <i>Journal of Zhejiang University: Science B</i> , 2015, 16, 796-804.	1.3	35
51	mTOR inhibition improves the immunomodulatory properties of human bone marrow mesenchymal stem cells by inducing COX-2 and PGE2. <i>Stem Cell Research and Therapy</i> , 2017, 8, 292.	2.4	35
52	Bilateral vs. unilateral endoscopic ultrasound-guided celiac plexus neurolysis for abdominal pain management in patients with pancreatic malignancy: a systematic review and meta-analysis. <i>Supportive Care in Cancer</i> , 2018, 26, 353-359.	1.0	34
53	Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion. <i>Journal of Hematology and Oncology</i> , 2021, 14, 113.	6.9	32
54	Disruption of microRNA-21 by TALEN leads to diminished cell transformation and increased expression of cell-environment interaction genes. <i>Cancer Letters</i> , 2015, 356, 506-516.	3.2	31

#	ARTICLE	IF	CITATIONS
55	High mobility group box-1 mediates hippocampal inflammation and contributes to cognitive deficits in high-fat high-fructose diet-induced obese rats. <i>Brain, Behavior, and Immunity</i> , 2019, 82, 167-177.	2.0	31
56	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 367.	7.1	31
57	Protein phosphatase PP1 negatively regulates the Toll-like receptor- and RIG-I-like receptor-triggered production of type I interferon by inhibiting IRF3 phosphorylation at serines 396 and 385 in macrophage. <i>Cellular Signalling</i> , 2014, 26, 2930-2939.	1.7	30
58	CAR T-cell treatment during the COVID-19 pandemic: Management strategies and challenges. <i>Current Research in Translational Medicine</i> , 2020, 68, 111-118.	1.2	30
59	T-cell-replete haploidentical transplantation versus autologous stem cell transplantation in adult acute leukemia: a matched pair analysis. <i>Haematologica</i> , 2015, 100, 558-564.	1.7	29
60	Haploidentical transplant in patients with myelodysplastic syndrome. <i>Blood Advances</i> , 2017, 1, 1876-1883.	2.5	28
61	Calcineurin Inhibitors Replacement by Ruxolitinib as Graft-versus-Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e128-e133.	2.0	28
62	Biomarkers for Chimeric Antigen Receptor T Cell Therapy in Acute Lymphoblastic Leukemia: Prospects for Personalized Management and Prognostic Prediction. <i>Frontiers in Immunology</i> , 2021, 12, 627764.	2.2	28
63	Mutations in epigenetic regulators are involved in acute lymphoblastic leukemia relapse following allogeneic hematopoietic stem cell transplantation. <i>Oncotarget</i> , 2016, 7, 2696-2708.	0.8	27
64	Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 713577.	1.3	27
65	Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 6384-6392.	3.2	27
66	Current development of chimeric antigen receptor T-cell therapy. <i>Stem Cell Investigation</i> , 2018, 5, 44-44.	1.3	26
67	Clinical characterization and risk factors associated with cytokine release syndrome induced by COVID-19 and chimeric antigen receptor T-cell therapy. <i>Bone Marrow Transplantation</i> , 2021, 56, 570-580.	1.3	25
68	Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Update: Genetic Pathogenesis. <i>Frontiers in Immunology</i> , 2021, 12, 624848.	2.2	25
69	Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study. <i>Oncolimmunology</i> , 2017, 6, e1277307.	2.1	24
70	CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study. <i>Annals of Hematology</i> , 2018, 97, 781-789.	0.8	24
71	New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 702644.	1.3	24
72	Carvedilol improved diabetic rat cardiac function depending on antioxidant ability. <i>Diabetes Research and Clinical Practice</i> , 2007, 75, 7-13.	1.1	23

#	ARTICLE	IF	CITATIONS
73	Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. <i>JAMA Network Open</i> , 2021, 4, e2034750.	2.8	23
74	Precise Gene Modification Mediated by TALEN and Single-Stranded Oligodeoxynucleotides in Human Cells. <i>PLoS ONE</i> , 2014, 9, e93575.	1.1	23
75	The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: Findings from the Global Burden of Disease 2019 Study and Projections to 2030. <i>Journal of Oncology</i> , 2022, 2022, 1-14.	0.6	23
76	Berbamine overcomes imatinib-induced neutropenia and permits cytogenetic responses in Chinese patients with chronic-phase chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2011, 94, 156-162.	0.7	22
77	Fibroblast activation protein protects bortezomib-induced apoptosis in multiple myeloma cells through β -catenin signaling pathway. <i>Cancer Biology and Therapy</i> , 2014, 15, 1413-1422.	1.5	22
78	The chromatin remodeling subunit Baf200 promotes normal hematopoiesis and inhibits leukemogenesis. <i>Journal of Hematology and Oncology</i> , 2018, 11, 27.	6.9	22
79	Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 1655.	1.3	22
80	Programmable System of Cas13-Mediated RNA Modification and Its Biological and Biomedical Applications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 677587.	1.8	22
81	Carvedilol protected diabetic rat hearts via reducing oxidative stress. <i>Journal of Zhejiang University: Science B</i> , 2006, 7, 725-731.	1.3	21
82	mTOR inhibitor rapamycin induce polymorphonuclear myeloid-derived suppressor cells mobilization and function in protecting against acute graft-versus-host disease after bone marrow transplantation. <i>Clinical Immunology</i> , 2018, 187, 122-131.	1.4	21
83	Dissecting LncRNA Roles in Renal Cell Carcinoma Metastasis and Characterizing Genomic Heterogeneity by Single-Cell RNA-seq. <i>Molecular Cancer Research</i> , 2018, 16, 1879-1888.	1.5	21
84	Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE and Calcineurin/NFAT and Glycolysis Pathways. <i>Advanced Science</i> , 2022, 9, e2103508.	5.6	21
85	A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 105.	2.8	20
86	Clinical implications of HLA locus mismatching in unrelated donor hematopoietic cell transplantation: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 27645-27660.	0.8	20
87	Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells. <i>Journal of Hematology and Oncology</i> , 2022, 15, 38.	6.9	20
88	A promising sword of tomorrow: Human β 1 T cell strategies reconcile allo-HSCT complications. <i>Blood Reviews</i> , 2016, 30, 179-188.	2.8	19
89	Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis. <i>American Journal of Hematology</i> , 2022, 97, 458-469.	2.0	19
90	$\langle \text{mml:math} \text{ xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"} \rangle \langle \text{mml:mi} \rangle \beta^3 \langle \text{mml:mi} \rangle \langle \text{mml:mi} \rangle \beta^1 \langle \text{mml:mi} \rangle \langle \text{mml:math} \rangle$ T Cell and Other Immune Cells Crosstalk in Cellular Immunity. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	0.9	18

#	ARTICLE	IF	CITATIONS
91	Raf Kinase Inhibitor Protein Preferentially Promotes TLR3-Triggered Signaling and Inflammation. <i>Journal of Immunology</i> , 2017, 198, 4086-4095.	0.4	18
92	Integration-defective lentiviral vector mediates efficient gene editing through homology-directed repair in human embryonic stem cells. <i>Nucleic Acids Research</i> , 2017, 45, e29-e29.	6.5	18
93	Quantitative characterization of T-cell repertoire alteration in Chinese patients with B-cell acute lymphocyte leukemia after CAR-T therapy. <i>Bone Marrow Transplantation</i> , 2019, 54, 2072-2080.	1.3	18
94	Biomechanical cues as master regulators of hematopoietic stem cell fate. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 5881-5902.	2.4	18
95	Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rar α Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 2286-2301.	1.1	17
96	Using Gene Editing to Establish a Safeguard System for Pluripotent Stem-Cell-Based Therapies. <i>IScience</i> , 2019, 22, 409-422.	1.9	17
97	Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis. <i>Bone Marrow Transplantation</i> , 2020, 55, 824-826.	1.3	17
98	Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 29-41.	1.3	17
99	Tyrosine supplement ameliorates murine aGVHD by modulation of gut microbiome and metabolome. <i>EBioMedicine</i> , 2020, 61, 103048.	2.7	17
100	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	1.3	17
101	Novel progresses of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. <i>Stem Cell Investigation</i> , 2021, 8, 1-1.	1.3	17
102	Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. <i>International Journal of Hematology</i> , 2009, 89, 445-451.	0.7	16
103	CXCR4 Antagonist AMD3100 Promotes Mesenchymal Stem Cell Mobilization in Rats Preconditioned with the Hypoxia-Mimicking Agent Cobalt Chloride. <i>Stem Cells and Development</i> , 2018, 27, 466-478.	1.1	16
104	Comparative transcriptomic analysis of hematopoietic system between human and mouse by Microwell-seq. <i>Cell Discovery</i> , 2018, 4, 34.	3.1	16
105	Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies. <i>Cell Transplantation</i> , 2020, 29, 096368972091943.	1.2	16
106	Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies. <i>Cell Transplantation</i> , 2021, 30, 096368972110255.	1.2	16
107	A synthetic three-dimensional niche system facilitates generation of functional hematopoietic cells from human-induced pluripotent stem cells. <i>Journal of Hematology and Oncology</i> , 2016, 9, 102.	6.9	15
108	Different screening frequencies of carbapenem-resistant Enterobacteriaceae in patients undergoing hematopoietic stem cell transplantation: which one is better?. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 49.	1.5	15

#	ARTICLE	IF	CITATIONS
109	miR-4999-5p Predicts Colorectal Cancer Survival Outcome and Reprograms Glucose Metabolism by Targeting PRKAA2. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 1199-1210.	1.0	15
110	Risk Factors for Graft-Versus-Host Disease After Transplantation of Hematopoietic Stem Cells from Unrelated Donors in the China Marrow Donor Program. <i>Annals of Transplantation</i> , 2017, 22, 384-401.	0.5	15
111	Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. <i>EBioMedicine</i> , 2018, 36, 252-265.	2.7	14
112	Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis. <i>Cancer Management and Research</i> , 2019, Volume 11, 4129-4142.	0.9	14
113	Antithymocyte globulin improves GVHD-free and relapse-free survival in unrelated hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1668-1675.	1.3	14
114	How to Combine the Two Landmark Treatment Methods "Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?. <i>Frontiers in Immunology</i> , 2020, 11, 611710.	2.2	14
115	CRS-related coagulopathy in BCMA targeted CART-T therapy: a retrospective analysis in a phase I/II clinical trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1642-1650.	1.3	14
116	The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma. <i>PLoS ONE</i> , 2014, 9, e99174.	1.1	13
117	Rapamycin together with TGF- β 1, IL-2 and IL-15 induces the generation of functional regulatory T cells from human peripheral blood mononuclear cells. <i>Journal of Immunological Methods</i> , 2014, 402, 82-87.	0.6	13
118	Green Tea Polyphenol Epigallocatechin-3-Gallate Promotes Reendothelialization in Carotid Artery of Diabetic Rabbits by Reactivating Akt/eNOS Pathway. <i>Frontiers in Pharmacology</i> , 2018, 9, 1305.	1.6	13
119	Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy. <i>Bone Marrow Transplantation</i> , 2019, 54, 969-972.	1.3	13
120	Phenotypical and Functional Characterization of Bone Marrow Mesenchymal Stem Cells in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1020-1028.	2.0	12
121	Progress and challenges in generating functional hematopoietic stem/progenitor cells from human pluripotent stem cells. <i>Cytotherapy</i> , 2015, 17, 344-358.	0.3	12
122	NR2F2 regulates bone marrow-derived mesenchymal stem cell-promoted proliferation of Reh cells. <i>Molecular Medicine Reports</i> , 2016, 14, 1351-1356.	1.1	12
123	Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia. <i>Annals of Hematology</i> , 2020, 99, 2679-2687.	0.8	12
124	Development of pancytopenia in a patient with COVID-19. <i>Journal of Medical Virology</i> , 2021, 93, 1219-1220.	2.5	12
125	Bach2 overexpression represses Th9 cell differentiation by suppressing IRF4 expression in systemic lupus erythematosus. <i>FEBS Open Bio</i> , 2021, 11, 395-403.	1.0	12
126	Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 664-672.	1.3	12

#	ARTICLE	IF	CITATIONS
127	Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.. Journal of Clinical Oncology, 2017, 35, 7028-7028.	0.8	12
128	Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse. Frontiers in Oncology, 2021, 11, 750218.	1.3	12
129	Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering. Frontiers in Oncology, 2021, 11, 790299.	1.3	12
130	Ruxolitinib combined with etanercept induce a rapid response to corticosteroidâ€refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multiâ€center prospective study. American Journal of Hematology, 2020, 95, 1075-1084.	2.0	11
131	A novel <i>HNRNPC</i> fusion in acute promyelocytic leukaemia lacking <i>PML</i> rearrangement, sensitive to venetoclaxâ€based therapy. British Journal of Haematology, 2021, 195, e123-e128.	1.2	11
132	CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study. Blood, 2020, 136, 34-34.	0.6	11
133	Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy. Cancer Research and Treatment, 2018, 50, 1462-1466.	1.3	11
134	T Repleted Haploidentical Mismatch Allogeneic Versus Autologous Hematopoietic Stem Cell Transplantation In Adult Patients With Acute Leukemia In Complete Remission (CR): A pair-Matched Analysis From The Acute Leukemia Working Party Of EBMT. Blood, 2013, 122, 3359-3359.	0.6	11
135	Phase I open-label single arm study of GPRC5D CAR T-cells (OriCAR-017) in patients with relapsed/refractory multiple myeloma (POLARIS).. Journal of Clinical Oncology, 2022, 40, 8004-8004.	0.8	11
136	Epithelial disruption of Gab1 perturbs surfactant homeostasis and predisposes mice to lung injuries. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L1149-L1159.	1.3	10
137	Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis. Scientific Reports, 2019, 9, 20402.	1.6	10
138	Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 956-964.	2.0	10
139	Tandem fecal microbiota transplantation cycles in an allogeneic hematopoietic stem cell transplant recipient targeting carbapenem-resistant Enterobacteriaceae colonization: a case report and literature review. European Journal of Medical Research, 2021, 26, 37.	0.9	10
140	Follicular regulatory T cell biology and its role in immune-mediated diseases. Journal of Leukocyte Biology, 2021, 110, 239-255.	1.5	10
141	Matrine Cooperates with All-Trans Retinoic Acid on Differentiation Induction of All-Trans Retinoic Acid-Resistant Acute Promyelocytic Leukemia Cells (NB4-LR1): Possible Mechanisms. Planta Medica, 2014, 80, 399-408.	0.7	9
142	Restoration of CCAAT enhancer binding protein β P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells. International Journal of Oncology, 2015, 47, 1685-1695.	1.4	9
143	A Member of the Nuclear Receptor Superfamily, Designated as NR2F2, Supports the Self-Renewal Capacity and Pluripotency of Human Bone Marrow-Derived Mesenchymal Stem Cells. Stem Cells International, 2016, 2016, 1-11.	1.2	9
144	Reduction of Foxp3+ T cell subsets involved in incidence of chronic graftâ€versusâ€host disease after allogeneic hematopoietic stem cell transplantation. Hematological Oncology, 2017, 35, 118-124.	0.8	9

#	ARTICLE	IF	CITATIONS
145	Sequential treatment combining cladribine-based re-induction, myeloablative allogeneic HSCT, and prophylactic donor lymphocyte infusion: a promising treatment for refractory acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 2479-2490.	0.8	9
146	Generation of hematopoietic cells from mouse pluripotent stem cells in a 3D culture system of self-assembling peptide hydrogel. <i>Journal of Cellular Physiology</i> , 2020, 235, 2080-2090.	2.0	9
147	Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma. <i>Medicine (United States)</i> , 2020, 99, e22510.	0.4	9
148	Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data. <i>Frontiers in Pharmacology</i> , 2020, 11, 561601.	1.6	9
149	Detection and analysis of clinical features of patients with different types of coronavirus disease 2019. <i>Journal of Medical Virology</i> , 2021, 93, 401-408.	2.5	9
150	Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 610500.	2.2	9
151	Metabolic reprogramming of myeloid-derived suppressor cells: An innovative approach confronting challenges. <i>Journal of Leukocyte Biology</i> , 2021, 110, 257-270.	1.5	9
152	The 68-kDa Telomeric Repeat Binding Factor 1 (TRF1)-associated Protein (TAP68) Interacts with and Recruits TRF1 to the Spindle Pole during Mitosis. <i>Journal of Biological Chemistry</i> , 2014, 289, 14145-14156.	1.6	8
153	Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma. <i>Bone Marrow Transplantation</i> , 2018, 53, 1340-1344.	1.3	8
154	Epigenetic regulation of hematopoietic stem cell homeostasis. <i>Blood Science</i> , 2019, 1, 19-28.	0.4	8
155	Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1476-1478.	1.3	8
156	A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma. <i>Frontiers of Medicine</i> , 2020, 14, 711-725.	1.5	8
157	Bullous and Exanthematous Lesions Associated With Chimeric Antigen Receptor T-Cell Therapy in a Patient With Diffuse Large B-Cell Lymphoma. <i>JAMA Dermatology</i> , 2020, 156, 1026.	2.0	8
158	The oncometabolite R-2-hydroxyglutarate dysregulates the differentiation of human mesenchymal stromal cells via inducing DNA hypermethylation. <i>BMC Cancer</i> , 2021, 21, 36.	1.1	8
159	Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 641910.	2.2	8
160	Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Pharmacology</i> , 2021, 12, 668825.	1.6	8
161	BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement. <i>Journal of Immunotherapy</i> , 2021, Publish Ahead of Print, 25-34.	1.2	8
162	The Safety and Efficacy of a CRISPR/Cas9-Engineered Universal CAR-T Cell Product (CTA101) in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 52-52.	0.6	8

#	ARTICLE	IF	CITATIONS
163	The key role of PML in IFN- γ induced cellular senescence of human mesenchymal stromal cells. <i>International Journal of Oncology</i> , 2015, 46, 351-359.	1.4	7
164	On signaling pathways: hematopoietic stem cell specification from hemogenic endothelium. <i>Science China Life Sciences</i> , 2015, 58, 1256-1261.	2.3	7
165	PTPN21 Overexpression Promotes Osteogenic and Adipogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells but Inhibits the Immunosuppressive Function. <i>Stem Cells International</i> , 2019, 2019, 1-19.	1.2	7
166	Incidence, risk factors and outcome of extramedullary relapse after allogeneic hematopoietic stem cell transplantation in patients with adult acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2020, 99, 2639-2648.	0.8	7
167	Preemptive low-dose interleukin-2 or DLI for late-onset minimal residual disease in acute leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2021, 100, 517-527.	0.8	7
168	Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 672052.	1.3	7
169	Enhanced HSC-like cell generation from mouse pluripotent stem cells in a 3D induction system cocultured with stromal cells. <i>Stem Cell Research and Therapy</i> , 2021, 12, 353.	2.4	7
170	Profile of Capillary-Leak Syndrome in Patients Received Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2018, 132, 5204-5204.	0.6	7
171	Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2022, 97, E44.	2.0	7
172	Effect of donor characteristics on T cell-replete haploidentical stem cell transplantation over the last 10 years at a single institution. <i>British Journal of Haematology</i> , 2022, 196, 1225-1238.	1.2	7
173	NEDD4L binds the proteasome and promotes autophagy and bortezomib sensitivity in multiple myeloma. <i>Cell Death and Disease</i> , 2022, 13, 197.	2.7	7
174	Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2022, 5, e226114.	2.8	7
175	Significance of clinical factors as prognostic indicators for patients with peripheral T-cell non-Hodgkin lymphoma: A retrospective analysis of 252 cases. <i>Molecular and Clinical Oncology</i> , 2013, 1, 911-917.	0.4	6
176	Cunninghamella bertholletiae Infection in a HLA-Haploidentical Hematopoietic Stem Cell Transplant Recipient with Graft Failure: Case Report and Review of the Literature. <i>Mycopathologia</i> , 2016, 181, 753-758.	1.3	6
177	Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report. <i>BMC Cancer</i> , 2019, 19, 242.	1.1	6
178	Activation-induced cytidine deaminase overexpression in double-hit lymphoma: potential target for novel anticancer therapy. <i>Scientific Reports</i> , 2020, 10, 14164.	1.6	6
179	Obesity is correlated with poor outcome after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 889-896.	0.6	6
180	CD19/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations. <i>Bone Marrow Transplantation</i> , 2020, 55, 717-721.	1.3	6

#	ARTICLE	IF	CITATIONS
181	Maintenance sorafenib is superior to prophylactic donor lymphocyte infusion at improving the prognosis of acute myeloid leukemia with FMS-like tyrosine kinase 3 internal tandem duplication after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 293-296.	1.3	6
182	Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients With Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 614488.	2.2	6
183	A Novel Strategy for the Prevention of Hepatitis B Virus-Related Hepatitis Following Allogeneic Hematopoietic Stem Cell Transplantation from Hepatitis B Surface Antigen-Positive Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1719-1728.	2.0	6
184	Bone Marrow Microenvironment Is a New Therapeutic Target of Ruxolitinib in Myeloproliferative Neoplasm. <i>Blood</i> , 2014, 124, 2930-2930.	0.6	6
185	Successful BCMA CAR-T Therapy for Multiple Myeloma With Central Nervous System Involvement Manifesting as Cauda Equina Syndrome—A Wandering Road to Remission. <i>Frontiers in Oncology</i> , 2021, 11, 755584.	1.3	6
186	Opioid receptor signaling suppresses leukemia through both catalytic and non-catalytic functions of TET2. <i>Cell Reports</i> , 2022, 38, 110253.	2.9	6
187	Cytomegalovirus Retinitis and Retinal Detachment following Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma. <i>Current Oncology</i> , 2022, 29, 490-496.	0.9	6
188	Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2016, 11, e0163599.	1.1	5
189	Hydroxychloroquine sensitizes chronic myeloid leukemia cells to γ T cell-mediated lysis independent of autophagy. <i>International Journal of Oncology</i> , 2017, 50, 1810-1820.	1.4	5
190	Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT. <i>Regenerative Therapy</i> , 2019, 11, 139-142.	1.4	5
191	Simplified MIPI-B prognostic stratification method can predict the outcome well—retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China. <i>Medicine (United States)</i> , 2019, 98, e13741.	0.4	5
192	HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human γ T Cells. <i>Molecular Therapy - Oncolytics</i> , 2020, 18, 623-630.	2.0	5
193	Silencing of microRNA miR-175 represses cell proliferation and invasion in prostate cancer by targeting the potential tumor suppressor SCN4B. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 20-26.	0.8	5
194	Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. <i>Journal of Cancer</i> , 2021, 12, 5423-5431.	1.2	5
195	Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies. <i>Current Medical Science</i> , 2021, 41, 420-430.	0.7	5
196	The Key Gene Expression Patterns and Prognostic Factors in Malignant Transformation from Enchondroma to Chondrosarcoma. <i>Frontiers in Oncology</i> , 2021, 11, 693034.	1.3	5
197	Cell subsets and cytokine dynamics in cerebrospinal fluid after CAR-T cell therapy for B-cell acute lymphoblastic leukemia with central nervous system involvement. <i>Bone Marrow Transplantation</i> , 2021, 56, 3088-3090.	1.3	5
198	Tip of the iceberg: roles of circRNAs in hematological malignancies. <i>American Journal of Cancer Research</i> , 2020, 10, 367-382.	1.4	5

#	ARTICLE	IF	CITATIONS
199	Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 1353-1360.	0.8	4
200	Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy. <i>Regenerative Therapy</i> , 2020, 15, 281-284.	1.4	4
201	CAR-T cells: the Chinese experience. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1293-1308.	1.4	4
202	Thymic rebound hyperplasia post-chemotherapy mistaken as disease progression in a patient with lymphoma involving mediastinum: a case report and reflection. <i>BMC Surgery</i> , 2021, 21, 38.	0.6	4
203	Comparison of non-first-degree related donors and first-degree related donors in haploidentical HSCT: a multi-centre retrospective analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 2567-2574.	1.3	4
204	Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 695-700.	1.3	4
205	COVID-19 in Hematologic Malignancies: Big Challenges. <i>Clinical Hematology International</i> , 2020, 2, 173.	0.7	4
206	Association Between TNF and TNF Receptor II Gene Polymorphisms and Acute Graft-Versus-Host Disease in Unrelated Donor Allogeneic Haematopoietic Stem Cell Transplantation within Chinese Population.. <i>Blood</i> , 2009, 114, 1158-1158.	0.6	4
207	A Pilot Prospective Single-Arm Clinical Study on Decitabine Plus CAG or IA Followed with HLA-Mismatched Nonmyeloablative Transplantation (micro transplantation) on De Novo Elderly Acute Myeloid Leukemia and Int-2/High Risk Myelodysplastic Syndrome Patients. <i>Blood</i> , 2018, 132, 2188-2188.	0.6	4
208	Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies. <i>Cancer Letters</i> , 2022, 538, 215691.	3.2	4
209	Carvedilol Protects Early Diabetic Rat Hearts through Reducing Oxidative Stress. , 2005, 2006, 929-32.		3
210	Shorter- versus Longer-duration Dual Antiplatelet Therapy in Patients with Diabetes Mellitus Undergoing Drug-eluting Stents Implantation. <i>Chinese Medical Journal</i> , 2016, 129, 2861-2867.	0.9	3
211	Generation of human iPSCs from an essential thrombocythemia patient carrying a V501L mutation in the MPL gene. <i>Stem Cell Research</i> , 2017, 18, 57-59.	0.3	3
212	<i>Withdrawal</i>: Generation of hematopoietic cells from mouse pluripotent stem cells in a 3D culture system of self-assembling peptide hydrogel. <i>Journal of Cellular Physiology</i> , 2019, 234, 16654-16654.	2.0	3
213	PTPN21â€™CDS long isoform inhibits the response of acute lymphoblastic leukemia cells to NKâ€™mediated lysis via the KIR/HLAâ€™ axis. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 3298-3312.	1.2	3
214	Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy. <i>Regenerative Therapy</i> , 2020, 14, 271-274.	1.4	3
215	Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib. <i>Regenerative Therapy</i> , 2020, 14, 40-42.	1.4	3
216	Generation of a FTO gene knockout human embryonic stem cell line using CRISPR/Cas9 editing. <i>Stem Cell Research</i> , 2021, 53, 102362.	0.3	3

#	ARTICLE	IF	CITATIONS
217	Inflammation-related genes S100s, RNASE3, and CYBB and risk of leukemic transformation in patients with myelodysplastic syndrome with myelofibrosis. <i>Biomarker Research</i> , 2021, 9, 53.	2.8	3
218	Efficacy of CD19-targeted chimeric antigen receptor T cells in the treatment of relapsed extramedullary B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2017, 35, e14549-e14549.	0.8	3
219	Isoflurane Preconditioning Protects the Myocardium Against Ischemia and Reperfusion Injury by Upregulating GRM1 Expression. <i>Current Neurovascular Research</i> , 2020, 17, 171-176.	0.4	3
220	Efficacy of Intermittent, Oral Famciclovir Prophylaxis for Bortezomib-Induced Herpes Zoster in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2022, 12, 843032.	1.3	3
221	Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia. <i>Chinese Medical Journal</i> , 2016, 129, 2512-2513.	0.9	2
222	Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in a Clinical Practice Setting in China. <i>Clinical Therapeutics</i> , 2017, 39, 1758-1768.	1.1	2
223	Single-cell qPCR facilitates the optimization of hematopoietic differentiation in hPSCs/OP9 coculture system. <i>Brazilian Journal of Medical and Biological Research</i> , 2018, 51, e7183.	0.7	2
224	The association of the UHRF1BP1 gene with systemic lupus erythematosus was replicated in a Han Chinese population from mainland China. <i>Annals of Human Genetics</i> , 2020, 84, 221-228.	0.3	2
225	Successful Treatment of Pyoderma Gangrenosum With Skin Grafting in a Patient With Acute Lymphoblastic Leukemia. <i>Dermatologic Surgery</i> , 2020, 46, 421-423.	0.4	2
226	The CD226-ERK1/2-LAMP1 pathway is an important mechanism for V β 39V γ 2 T cell cytotoxicity against chemotherapy-resistant acute myeloid leukemia blasts and leukemia stem cells. <i>Cancer Science</i> , 2021, 112, 3233-3242.	1.7	2
227	Cytokine Release Syndrome Is an Independent Risk Factor Associated With Platelet Transfusion Refractoriness After CAR-T Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia. <i>Frontiers in Pharmacology</i> , 2021, 12, 702152.	1.6	2
228	Non-BCMA targeted CAR-T cell therapies for multiple myeloma. <i>Immunomedicine</i> , 2021, 1, e1030.	0.7	2
229	PTPN21 Plays a Role in Occurrence and Relapse of Acute Lymphoblastic Leukemia By Promoting the Proliferation of Acute Lymphoblastic Leukemic Cells Via Activating MAPK Signal Pathways. <i>Blood</i> , 2016, 128, 5084-5084.	0.6	2
230	Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8525-8525.	0.8	2
231	Sumoylation of TRF1 Is Essential for Its Recruitment to ALT-Associated PML Bodies.. <i>Blood</i> , 2007, 110, 4169-4169.	0.6	2
232	Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China. <i>Medical Science Monitor</i> , 2018, 24, 5258-5270.	0.5	2
233	Weathering the storm: COVID-19 infection in patients with hematological malignancies. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 921-939.	1.3	2
234	Integrated Single-Cell Bioinformatics Analysis Reveals Intrinsic and Extrinsic Biological Characteristics of Hematopoietic Stem Cell Aging. <i>Frontiers in Genetics</i> , 2021, 12, 745786.	1.1	2

#	ARTICLE	IF	CITATIONS
235	Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: a multi-institutional experience from an HBV endemic area. <i>Annals of Hematology</i> , 2022, 101, 631-641.	0.8	2
236	Profile of capillary-leak syndrome in patients received chimeric antigen receptor T cell therapy. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	2
237	Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2022, 13, 829670.	2.2	2
238	mTOR Signaling Regulates the Development and Therapeutic Efficacy of PMN-MDSCs in Acute GVHD. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 741911.	1.8	2
239	Impact of Donor-to-Recipient ABO Mismatch on Outcomes of Antithymocyte Globulin-Based Peripheral Blood Stem Cell-Derived Myeloablative Conditioning Haploidentical Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	2
240	Case Report: Chanarin-Dorfman Syndrome: A Novel Homozygous Mutation in ABHD5 Gene in a Chinese Case and Genotype-Phenotype Correlation Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 847321.	1.1	2
241	Efficient expansion of rare human circulating hematopoietic stem/progenitor cells in steady-state blood using a polypeptide-forming 3D culture. <i>Protein and Cell</i> , 2022, 13, 808-824.	4.8	2
242	Cyclosporine A regulates PMN-MDSCs viability and function through MPTP in acute GVHD: old medication, new target. <i>Transplantation and Cellular Therapy</i> , 2022, , .	0.6	2
243	Predictive value of next-generation sequencing-based minimal residual disease after CAR-T cell therapy. <i>Bone Marrow Transplantation</i> , 2022, 57, 1350-1353.	1.3	2
244	Pomalidomide-based regimens bridging CAR-T therapy in multiple myeloma with central nervous system involvement. <i>Regenerative Therapy</i> , 2022, 21, 34-36.	1.4	2
245	Invasive pulmonary fungal infection accompanied by severe hemoptysis in patients with hematologic diseases: a report of nine cases. <i>International Journal of Hematology</i> , 2009, 90, 108-112.	0.7	1
246	The Exploration and Practice of the Comprehensive Reform in Graduate Education on Professional Degree of Clinical Medicine. <i>Chinese Education and Society</i> , 2014, 47, 97-102.	0.3	1
247	IL-17-producing $\gamma\delta$ T cells ameliorate intestinal acute graft-versus-host disease by recruitment of Gr-1+CD11b+ myeloid-derived suppressor cells. <i>Bone Marrow Transplantation</i> , 2021, 56, 2389-2399.	1.3	1
248	Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Data in China. <i>Frontiers in Oncology</i> , 2021, 11, 665217.	1.3	1
249	Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: A phase III randomized controlled study. <i>American Journal of Hematology</i> , 2021, 96, 1429-1440.	2.0	1
250	Specific Blood Cells Derived from Pluripotent Stem Cells: An Emerging Field with Great Potential in Clinical Cell Therapy. <i>Stem Cells International</i> , 2021, 2021, 1-16.	1.2	1
251	Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies. <i>Blood</i> , 2019, 134, 3220-3220.	0.6	1
252	Generation, Characterization and Genetic Modification of Human iPSCs Containing Calr, MPL and JAK2 Mutations Found in MPN Patients. <i>Blood</i> , 2016, 128, 3139-3139.	0.6	1

#	ARTICLE	IF	CITATIONS
253	Oridonin, An Ent-Kaurane Diterpenoid, Shows Antileukemic Effect and Enhances the Effect of Indarubicin on Human T-Cell Leukemia Cell Line. <i>Blood</i> , 2010, 116, 4933-4933.	0.6	1
254	Foxp3+ Regulatory T Cell Subsets Are Induced In Alloreactive Microenvironment and Associated With Chronic Graft-Versus-Host Disease Severity After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3307-3307.	0.6	1
255	The Expression Of CD200 As a Prognostic Factor In Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3082-3082.	0.6	1
256	Matched Sibling Versus Haploidentical Hematopoietic Transplant for Adult Patients with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2295-2295.	0.6	1
257	Interactions Between BAFF and BAFF Receptors Are Involved in Macrophage-Induced Bortezomib Resistance in Myeloma. <i>Blood</i> , 2016, 128, 4429-4429.	0.6	1
258	Changes of T Lymphocyte Subsets after CAR-T Cell Therapy and Its Clinical Significance. <i>Blood</i> , 2018, 132, 1423-1423.	0.6	1
259	CCL2 Promotes Macrophages-Associated Chemoresistance Via MCP1 Dual Catalytic Activities in Multiple Myeloma. <i>Blood</i> , 2019, 134, 3086-3086.	0.6	1
260	Acute myeloid leukemia of a primary hepatic carcinoma patient after liver transplantation: a case report and literature review. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 13655-60.	0.5	1
261	Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation. <i>American Journal of Cancer Research</i> , 2021, 11, 3111-3122.	1.4	1
262	Comparison of Prophylactic and Preemptive Donor Lymphocyte Infusion in Patients with Very High Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3860-3860.	0.6	1
263	Clinical Characterization and Risk Factors Associated with Cytokine Release Syndrome Induced By COVID-19 and Chimeric Antigen Receptor T-Cell Therapy. <i>Blood</i> , 2020, 136, 35-36.	0.6	1
264	Ruxolitinib for Steroid-Refractory cGvHD: A Significant Response in Heavily Pretreated Patients after Haploidentical-SCT. <i>Blood</i> , 2020, 136, 1-1.	0.6	1
265	Outcomes of CD19 chimeric antigen receptor T cell followed by haploidentical hematopoietic stem-cell transplantation in relapsed/refractory B-cell acute lymphoblastic leukemia with IKZF1 deletion. <i>Bone Marrow Transplantation</i> , 2022, 57, 326-328.	1.3	1
266	Chronic graft-versus-host disease-related polymyositis and myocarditis: A case report and review of the literature. <i>Transplant Immunology</i> , 2022, 72, 101598.	0.6	1
267	CAR-T cells for cancer immunotherapy—the barriers ahead and the paths through. <i>International Reviews of Immunology</i> , 2022, 41, 567-581.	1.5	1
268	Cloning and high expression of full length hTRF1 in E. Coli. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2001, 13, 179-180.	0.7	0
269	The effectiveness of interferon- γ combined with imatinib in patient with chronic myeloid leukemia harboring T3151 <i>c</i> BCR-ABL1 <i>b3</i> mutation. <i>Leukemia and Lymphoma</i> , 2018, 59, 3018-3019.	0.6	0
270	Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas. <i>Journal of Neuro-Oncology</i> , 2019, 143, 369-379.	1.4	0

#	ARTICLE	IF	CITATIONS
271	Toll-like Receptor 4 Gene Polymorphisms in Chinese Population After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Current Bioinformatics</i> , 2021, 16, 225-229.	0.7	0
272	Successful treatment of early onset Epstein-Barr virus-negative T-cell lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation with histone deacetylase inhibitor chidamide. <i>Chinese Medical Journal</i> , 2021, Publish Ahead of Print, 2756-2758.	0.9	0
273	Generation of an ELTD1 knockout human embryonic stem cell line by the iCRISPR/Cas9 system. <i>Stem Cell Research</i> , 2021, 53, 102350.	0.3	0
274	Non-Ablative Chemotherapy Followed by HLA-Mismatched Allogeneic CD3+ T-Cells Infusion Causes An Augment of T-Cells With Mild CRS: A Multi-Centers Single-Arm Prospective Study on Elderly Acute Myeloid Leukemia and int-2/High Risk Myelodysplastic Syndrome Patients. <i>Frontiers in Oncology</i> , 2021, 11, 741341.	1.3	0
275	The Effect of Dipeptiven in Patients after Allogenic Hematologic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 5371-5371.	0.6	0
276	Chromosomal Instability Induced by Overexpression of Telomere Repeats Binding Factor 1.. <i>Blood</i> , 2005, 106, 4398-4398.	0.6	0
277	Tandem Autotransplants™ Peripheral Blood Stem Cells Following Sequent High-Dose CHEOP Chemotherapy for Aggressive Lymphoma.. <i>Blood</i> , 2005, 106, 5510-5510.	0.6	0
278	Clinical Investigation of G-CSF-Priming Regimen in Treatment of Relapsing, Refractory and Senile Acute Myeloid Leukemia.. <i>Blood</i> , 2005, 106, 4620-4620.	0.6	0
279	Effects of Apoptosis in Human Activated Peripheral T-Lymphocytes by Immunosuppressive Drugs.. <i>Blood</i> , 2005, 106, 5219-5219.	0.6	0
280	Candida tropicalis Arthritis of the Knee in a Patient with Acute Monocytic Leukemia.. <i>Blood</i> , 2006, 108, 3867-3867.	0.6	0
281	Proteinase-Activated Receptor 1 Expression in Human Leukemia HL-60 Cells and Its Significance.. <i>Blood</i> , 2006, 108, 4484-4484.	0.6	0
282	Biological Characteristics of ZUC3 Antigen Expressed on Rat Bone Marrow Mesenchymal Stem Cells.. <i>Blood</i> , 2006, 108, 4254-4254.	0.6	0
283	Unrelated Donor Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in First Complete Remission.. <i>Blood</i> , 2007, 110, 5077-5077.	0.6	0
284	The Value of CT-Guided Percutaneous Lung Biopsy in the Diagnosis of Pulmonary Fungal Infections in Patients with Hematologic Diseases.. <i>Blood</i> , 2007, 110, 3860-3860.	0.6	0
285	The Research of Phenylhexyl Isothiocyanate™s Influence on p16 Gene Methylation of Leukaemia Cell. <i>Blood</i> , 2008, 112, 4497-4497.	0.6	0
286	Neurological Complications Following Allogeneic Haematopoietic Stem Cell Transplantation. <i>Blood</i> , 2008, 112, 4307-4307.	0.6	0
287	Bronchiolitis Obliterans Following Unrelated-Donor Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2010, 116, 4504-4504.	0.6	0
288	Evaluation the Risk Factor of Transplantation-Associated Thrombotic Microangiopathy.. <i>Blood</i> , 2010, 116, 4527-4527.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Allogeneic Hematopoietic Stem Cell Transplantation From HBsAg-Positive Donors Into HBsAg-Negative Recipients: A Safety and Practicable Regimen Under Active Prophylactic Anti-HBV Therapy. <i>Blood</i> , 2011, 118, 1949-1949.	0.6	0
290	Ex Vivo-Expanded $\text{V}\alpha\text{3}\text{V}\beta\text{2}$ T Cells Can Efficiently Kill Human Acute Myeloid Leukemia Cells Via Trogocytosis. <i>Blood</i> , 2011, 118, 580-580.	0.6	0
291	Clinical Characteristics and Outcome of Isolated Extramedullary Relapse in Acute Leukemia Following Allogeneic Stem Cell Transplantation: A Single Institutional Analysis. <i>Blood</i> , 2012, 120, 4211-4211.	0.6	0
292	Combination Therapy Based on Bortezomib for Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 5048-5048.	0.6	0
293	Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 1433-1433.	0.6	0
294	Homoharringtonine In Combination With Cytarabine and Etoposide For Induction Therapy In Patients With De Novo Acute Myelogenous Leukemia. <i>Blood</i> , 2013, 122, 5006-5006.	0.6	0
295	Prospective Evaluation Of Allo-HSCT From Haploidentical-Related Donors Compared With Matched Sibling Donors and Unrelated Donors For Patients With Hematological Malignancies: Results From An Open-Label Trial. <i>Blood</i> , 2013, 122, 3338-3338.	0.6	0
296	Comparison of Allogeneic Hematopoietic Stem Cell Transplant from HLA-Matched Related Donors and from Unrelated Donors for Intermediate- to High-Risk Adult Acute Myeloid Leukemia in Remission. <i>Blood</i> , 2014, 124, 5946-5946.	0.6	0
297	Serum Ferritin Was the Only Prognostic Factor for Disease Free Survival in MDS Patients after Allo-HSCT: A Single Centre Study. <i>Blood</i> , 2014, 124, 5859-5859.	0.6	0
298	Unrelated Cord Blood Versus Non-T Cell Depleted Haploidentical Stem Cell Transplantation: Comparable Results in Adults with Acute Leukemia, a Eurocord and ALWP-EBMT Study. <i>Blood</i> , 2014, 124, 1227-1227.	0.6	0
299	FLT3-ITD As a Prognostic Factor for Chinese Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5256-5256.	0.6	0
300	Regular Prophylactic Donor Lymphocyte Infusion Is Effective and Safe to Prevent Relapse after Hematopoietic Cell Transplantation in High-Risk Patients. <i>Blood</i> , 2016, 128, 3439-3439.	0.6	0
301	Expansion of CD56-Bright NK Cell in Patients with Steroid-Refractory Graft-Versus-Host Disease Treated with Basiliximab and Etanercept. <i>Blood</i> , 2016, 128, 5793-5793.	0.6	0
302	Eltrombopag Treatment for Patients with Thrombocytopenia Post-Transplantation Showed a Good Chance of Platelet Recovery. <i>Blood</i> , 2019, 134, 5658-5658.	0.6	0
303	Calcineurin Inhibitors Replacement By Ruxolitinib As Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 5674-5674.	0.6	0
304	Predictive Value of Next-Generation Sequencing-Based Minimal Residual Disease after CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 2842-2842.	0.6	0
305	Chimeric antigen receptor-engineered adoptive cell therapy for AML: Current status and future perspectives. <i>Immunomedicine</i> , 2022, 2, .	0.7	0
306	HLA-matched allogeneic anti-CD19 CAR-T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden. <i>Immunomedicine</i> , 2022, 2, .	0.7	0

#	ARTICLE	IF	CITATIONS
307	Abstract 3155: "Super NK cells" - natural killer cells derived from engineered hiPSC with enhanced NK receptor expression demonstrate better anti-tumor effects for solid tumors. Cancer Research, 2022, 82, 3155-3155.	0.4	0
308	Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) as second-line therapy for primary refractory Chinese patients with large B-cell lymphoma (LBCL): Results from an open-label, multicenter, single-arm phase I study.. Journal of Clinical Oncology, 2022, 40, e19509-e19509.	0.8	0
309	CAR T cell therapy in advanced Bâ€ALL with heavy disease burden. Immunomedicine, 0, , .	0.7	0